A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia

Jerald P. Radich*, Kenneth J. Kopecky, Frederick R. Appelbaum, Suzanne Kamel-Reid, Wendy Stock, Greg Malnassy, Elisabeth Paietta, Martha Wadleigh, Richard A. Larson, Peter Emanuel, Martin Tallman, Jeff Lipton, A. Robert Turner, Michael Deininger, Brian J. Druker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

146 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

INIS